TScan Therapeutics, Inc. (TCRX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-22

TScan Therapeutics, Inc. (TCRX) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-22. 3 Form 8-K material event filings were reported by TCRX in the last 90 days. InsiderAlpha tracks every TCRX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About TScan Therapeutics, Inc. (TCRX)

SEC CIK	0001783328

90-Day SEC Filing Activity

Form 4 filings (90d)	6
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-05-22

Recent TCRX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-12-23	Lynx1 Capital Management LP	10% Owner	P — Open-market purchase	6.2K	$0.90	$6K	SEC
2025-12-22	Lynx1 Capital Management LP	10% Owner	P — Open-market purchase	75.5K	$0.90	$68K	SEC
2025-12-19	Lynx1 Capital Management LP	10% Owner	P — Open-market purchase	80.1K	$0.90	$72K	SEC
2024-12-13	Lynx1 Capital Management LP	10% Owner	P — Open-market purchase	100.0K	$2.90	$290K	SEC
2024-12-12	Lynx1 Capital Management LP	10% Owner	P — Open-market purchase	31.8K	$3.01	$96K	SEC
2024-11-15	Lynx1 Capital Management LP	10% Owner	P — Open-market purchase	947	$4.34	$4K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for TScan Therapeutics, Inc. (TCRX). Updated in real time as new filings are submitted to the SEC.

Most-Active TCRX Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
BAKER BROS. ADVISORS LP	2	—
Dorton Katina	1	—
Nicholson Garry A	1	—
Klencke Barbara	1	—
Woods Keith	1	—

Recent TCRX Form 8-K Material Events

2026-06-22 — Item 7.01, 8.01, 9.01 [SEC]
2026-05-22 — Item 5.03, 5.07, 9.01 [SEC]
2026-05-06 — Item 2.02, 9.01 [SEC]
2026-04-02 — Item 5.02 · Leadership · neutral [SEC]
Vice President of Finance Leiden Dworak resigned effective April 10, 2026. CFO Jason A. Amello was appointed as principal accounting officer in addition to his existing CFO duties, with no additional compensation.
2026-03-04 — Item 2.02, 9.01 · Earnings · neutral [SEC]
TScan Therapeutics announced financial results for Q4 and fiscal year 2025 on March 4, 2026. The filing provides standard financial reporting without indication of beat, miss, or material guidance changes.

Recent Insider Filings

2026-05-22 — BAKER BROS. ADVISORS LP (Insider)
2026-05-22 — Woods Keith (Insider)
2026-05-22 — Nicholson Garry A (Insider)
2026-05-22 — Gruia Gabriela (Insider)
2026-05-22 — Dorton Katina (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in TCRX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

TCRX Insider Trading — FAQ

What is the latest insider trade for TCRX?: TScan Therapeutics, Inc. (TCRX) had 6 insider filings in the last 90 days, with the most recent on 2026-05-22. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying TCRX stock?: 0 insider purchases of TCRX were filed in the last 90 days.
How many insiders are selling TCRX stock?: 0 insider sales of TCRX were filed in the last 90 days.
Where can I see TCRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every TCRX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live TCRX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.